Patrys Limited (AU:PAB) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Patrys Limited has bolstered its financial standing by receiving a $1.285 million rebate through the Australian Government’s R&D Tax Incentive scheme. This refund supports the ongoing development of their innovative deoxymab platform, which targets cancer cells and inflammatory diseases. The company’s commitment to advancing these therapies could potentially revolutionize cancer treatment options.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.
